BKM120 for Patients With PI3K-activated Tumors

Clinical trial NCT01833169 · COMPLETED

Trial details

NCT number: NCT01833169
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

PI3K Pathway Activated Tumors

Start date: 2013-03-29
Primary completion: 2016-09-26
Enrollment: 146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.